Link to this page
Physician Data Query
Last uploaded:
August 27, 2019
Jump to:
| Preferred Name | zanamivir | |
| Synonyms |
Relenza |
|
| Definitions |
A sialic acid-analogue neuraminidase inhibitor with antiviral activity. Administered into the respiratory tract by aerosol inhalation, zanamivir selectively binds to and inhibits influenza A and B virus neuraminidase-mediated cleavage of sialic acid residues in host cell membrane-bound glycoprotein receptors for influenza viruses, preventing the release of progeny viruses from host cell surfaces and, so, further viral replication. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C47786" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C47786" NCI Thesaurus) |
|
| ID |
http://purl.bioontology.org/ontology/PDQ/CDR0000636195 |
|
| altLabel |
Relenza
|
|
| cui |
C0216660 C0876148
|
|
| DATE FIRST PUBLISHED |
2009-02-20
|
|
| Date last modified |
2009-09-18
|
|
| definition |
A sialic acid-analogue neuraminidase inhibitor with antiviral activity. Administered into the respiratory tract by aerosol inhalation, zanamivir selectively binds to and inhibits influenza A and B virus neuraminidase-mediated cleavage of sialic acid residues in host cell membrane-bound glycoprotein receptors for influenza viruses, preventing the release of progeny viruses from host cell surfaces and, so, further viral replication. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C47786" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C47786" NCI Thesaurus)
|
|
| LT |
TRD
|
|
| NCI ID |
C47786
|
|
| notation |
CDR0000636195
|
|
| ORIG STY |
Drug/agent
|
|
| prefLabel |
zanamivir
|
|
| tui |
T109 T121
|
Add comment
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |
Create mapping